A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 39/395 (2006.01) A61K 9/16 (2006.01) A61K 9/50 (2006.01) A61K 9/60 (2006.01) A61K 38/19 (2006.01) A61K 38/20 (2006.01)
Patent
CA 2192821
The invention pertains to a controlled release pharmaceutical formulation that has an effective amount of a polypeptide selected from the group consisting of: (a) TNFR, (b) IL-1R, (c) IL-1ra, (d) IL-6R and (e) a monoclonal antibody that is immunoreactive against TNF, IL-6 or IL-1; wherein the polypeptide is encapsulated in alginate. The invention also pertains to methods of treating inflammatory bowel disease by administering the above composition to a patient in need thereof.
Formulation pharmaceutique à libération lente comportant une quantité efficace d'un polypeptide sélectionné dans le groupe constitué de (a) TNFR, (b) IL-1R, (c) IL-1ra, (d) IL-6R et (e) un anticorps monoclonal immunoréactif vis-à-vis de TNF, IL-6 ou IL-1, ledit polypeptide étant encapsulé dans l'alginate. On a également prévu des procédés de traitement des affections intestinales inflammatoires par administration de ladite composition à un malade qui en a besoin.
Gombotz Wayne R.
Wee Siowfong
Immunex Corporation
Smart & Biggar
LandOfFree
Controlled release polypeptide compositions and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release polypeptide compositions and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release polypeptide compositions and methods of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1857879